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Lothian, Edinburgh, UKAbstractParvovirus B19 (B19V) infections are a common but under-investigated and under-reported cause of intrauterine infections. An increased
number of acute B19V infections was identiﬁed in the Edinburgh area in 2012–2013, with 123 infections diagnosed in 33 pregnant
women, 76 non-pregnant women and 14 men. All except one pregnant woman were asymptomatic. An overall infection rate of 18% was
measured in pregnant women who were tested following B19V exposure (26/141). Furthermore, a 7% seroconversion rate was
recorded in non-immune pregnant women who were re-tested after exposure (7/104). A high fetal loss rate (25%; 3/12) was observed in
those who had acute B19V infection in early pregnancy (<11 weeks) whereas all pregnancies progressed to term in those where acute
infection occurred after a gestational age of 12 weeks. These results suggest that more efforts should be targeted to investigate suspected
B19V infections in early pregnancy during epidemic seasons.
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E-mail: heli.simmonds@hotmail.comIntroductionParvovirus B19 (B19V) within the genus Erythrovirus belongs
to the Parvoviridae family. It is a classical cause of the child-
hood rash called erythema infectiosum (also known as ﬁfth
disease or slapped cheek syndrome). B19V infection is
generally a mild febrile illness, but in adults it often presents
with symmetrical arthralgia and in those with underlying
haemogobulinopathies or in the immunocompromised can
lead to sometimes life-threatening transient aplastic crisis [1].
Furthermore, infection in the ﬁrst 20 weeks of pregnancy is
associated with hydrops fetalis and intrauterine death [2–5].Clinical Microbiology and Infection © 2014 European Society of CTimely diagnosis of B19V infection during pregnancy is
important because the management of B91V infections has
become more active with intrauterine transfusion, which has
been shown to improve the outcome of hydrops fetalis [6,7].
However, this is difﬁcult to implement because B19V in-
fections are often asymptomatic in pregnancy, there is no
antenatal screening to identify those at risk for infection and
there is no public health and virological surveillance for B19V
infections in the community.
Southeast Scotland (i.e. Edinburgh area or NHS Lothian
Health Board) has a population of 800 000 that includes 130
000 females of reproductive age (between 18 and 40 years) and
registers approximately 12 000 pregnancies per annum [8].
These result in around 10 000 live births and approximately
2000 lost pregnancies. In general, it is recognized that 12–15%
of clinically recognized pregnancies miscarry [9]. However, only
approximately 150 miscarriages and 50 stillbirths are investi-
gated further in the Edinburgh area per annum. Efforts to
determine the role of B19V infections in sporadic fetal lossesClin Microbiol Infect 2015; 21: 193–196
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.09.009
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veillance is available.
The diagnosis of B19V infection in immunocompetent in-
dividuals is based on the detection of B19V IgG and IgM anti-
bodies. In most cases B19V-speciﬁc IgM antibodies are detected
early in infection, whereas B19V IgG antibodies appear weeks
later and remain detectable for life. Molecular detection
methods such as the PCR can also be used to support a diag-
nosis of acute B19V infection. During acute infection, B19V
DNA is present in blood samples at high level (up to 1014
particles/mL) but low B19V viral loads may remain detectable
throughout the life of some individuals.
This paper describes an increased number of B19V infections
in the Edinburgh area during the last season 2012–13, and
determines their potential impact as a cause of pregnancy loss.MethodsTABLE 1. Presentation of acute parvovirus B19 infections inDiagnostic methods
Diagnostic virology services are delivered by the Specialist
Virology laboratory at the Royal Inﬁrmary in Edinburgh. B19V
testing was carried out if B19V infection was clinically suspected
or if pregnant women had been in contact with a case of sus-
pected B19V infection. B19V IgG and IgM antibodies were
tested using commercial Biotrin assays (Diasorin, Saluggia, Italy)
according to the manufacturer’s instructions with the exception
of using the test-to-cutoff ratio >3.3 for determining IgM pos-
itivity to increase assay speciﬁcity. B19V PCR for DNA detec-
tion used a quantitative real-time PCR assay targeting the NS1
gene of the virus [10]. Although a strong single positive B19V
IgM test can be used as evidence of acute infection, all IgM-
positive samples were conﬁrmed using PCR or by demon-
strating IgG-seroconversion. Altogether, 31 from 33 IgM-
positive samples obtained from pregnant women were
conﬁrmed using B19V PCR; the remaining two samples were
not available for PCR testing but demonstrated IgG-
seroconversion. In addition, 15 pregnant women with acute
B19V infection demonstrated IgG-seroconversion either in
follow-up samples or in comparison with older stored blood
samples.Edinburgh 2012–13
Pregnant
females
Non-pregnant
females MalesResultsNumber of diagnoses 33 76 14
Mean age (range) 31 (17–40) 37 (6–77) 34 (6–62)
Presenting symptoms
Asymptomatic 32 (97%) 10 (13%) 0
Arthralgia only 1 (3%) 24 (32%) 3 (21%)
Rash only 0 10 (13%) 0
Arthralgia and rash 0 26 (34%) 6 (42%
Anaemia 0 6 (7.8%) 5 (36%)Parvovirus B19 infections July 2012 to June 2013
B19V infections. Testing of 1293 individuals for B19V between
July 2012 and June 2013 identiﬁed a total of 123 acute B19V
infections in the Edinburgh area. Most of these acute B19VClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectinfections were diagnosed in non-pregnant women (n = 76),
whereas 33 were diagnosed in pregnant women and 14 in men
(Table 1). The majority of non-pregnant females (86%) and all
males presented with clinical symptoms including arthralgia,
rash and anaemia, while most pregnant women were asymp-
tomatic (97%).
Follow up of non-immune pregnant women exposed to B19V
infection. Over a 6-month period of heightened transmission
between January 2013 and June 2013, 464 samples were
collected from pregnant women following exposure to B19V. A
total of 122 women were initially seronegative for B19V IgG
and IgM, whereas acute B19V infection was demonstrated in 19
pregnant women (only one with symptoms; arthralgia). Most of
the exposed women were entirely asymptomatic, with only six
recorded as symptomatic including rash, feeling unwell and
arthralgia (4.9%). Most B19V IgG-negative pregnant women
were followed up after 4 weeks from exposure (104/122; 85%);
seven of them developed acute asymptomatic B19V infection
(7/104; 6.7%). Miscarriage at the time of ﬁrst sample was
identiﬁed as a reason for non-follow-up in the post-exposure
period in 7/18 (39%) cases, whereas it is not known why the
remaining 11 cases were not followed up. Written advice for
further blood testing 4 weeks after exposure was given for all
non-immune, exposed individuals.
B19V request for maternal infection and outcome. Most pregnant
women found to have acute infection between July 2012 and
June 2013 were investigated because of a known B19V contact
(31/33) and only one of them presented with symptoms
(arthralgia). The remaining two cases were investigated after
miscarriage at 14 weeks; both booking samples obtained at
week 7 showed acute B19V infection in retrospective testing. A
total of 12 women worked with children as a teacher or
nursery nurse, and the remaining had other types of deﬁned
contacts (usually with their own or friends’ children). All 31
women were referred and followed up by the Department of
Fetal Medicine (Table 2). One woman lost her pregnancy at
week 18 before attending the specialist clinic. The remaining 30ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 193–196
TABLE 2. Acute parvovirus B19 infection in pregnant women
between 2010 and 2013
Year 2010–11 2011–12 2012–13 2010–13
Number of tests 544 610 1293 2447
Acute infections 4 3 33 40
Fetal loss 1 0 3 4
Hydrops fetalis 2 0 0 2
CMI Al Shukri et al. Parvovirus B19 and pregnancy 195pregnancies proceeded well; two women received intrauterine
blood transfusion due to their underlying illnesses (one with
platelet abnormality and one with thalassaemia). Five women
were shown to have been infected several weeks before the
testing was requested, in addition to those two who lost their
pregnancy. Six of the women had only IgM antibodies (i.e. IgG
antibody negative) at the time of testing.
Parvovirus B19 infections January 2008 to December
2013
B19V infections. For comparison, a total of 4980 individuals were
tested for B19V infection between January 2008 and December
2013; from those 265 acute B19V infections were identiﬁed in
the Edinburgh area (Fig. 1). Most of these acute B19V infections
were diagnosed in non-pregnant women (n = 192), whereas 49
were diagnosed in pregnant women and 24 in men (Table 2;
follow-up data aavailable from 2010 onwards).DiscussionAn increased number of acute B19V infections was observed in
the Edinburgh area in 2012–2013, with 33 from 123 acute in-
fections in pregnant women. The number of acute B19VFIG. 1. The number of laboratory-conﬁrmed parvovirus B19 infections in p
infections in the Edinburgh area per month between 2008 and 2013.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyinfections in pregnant women was very high in comparison to
the previous ﬁve years where fewer than ﬁve cases were
described annually (Fig. 1, Table 2) and also in comparison with
previous reports from Marseille and Belfast [11,12]. This is
despite the fact that the annual number of B19V tests has
remained relatively constant (i.e. 1092 in 2008 versus 1185 in
2013) and techniques for diagnosing acute B19V infection
remained unchanged. This increase is however consistent with
a previous study from Ireland that demonstrated a 6-year
periodicity for B19V infections and predicted the next epidemic
year around 2011–12 [13].
An overall B19V infection rate of 18% was measured in
pregnant women who were tested following a suspected
exposure or rash contact (26/141). Furthermore, a 7% sero-
conversion rate was recorded in non-immune pregnant women
who were re-tested after exposure. As reported previously
[12], there was a clear difference in the reason for testing
pregnant women and non-pregnant women or men; pregnant
women were tested because of exposure to suspected B19V
infection (or rash) and most of them remained asymptomatic
(95%), in contrast non-pregnant women and men were typically
tested because they presented with clinical symptoms (90%).
Hence awareness of the asymptomatic nature of B19V in-
fections during pregnancy is important for healthcare workers
managing these individuals, especially in B19V endemic years.
Although this study lacks systematic data on occupation or
other risk factors, the risk of acute B19V infection has been
associated with the intensity of exposure to children at home
and at work during B19V epidemics [14–16]. Furthermore,
follow up of those non-immune pregnant women exposed to
B19V needs to be improved to enable appropriate fetal moni-
toring and interventions.regnant women and the overall detection rate of acute parvovirus B19
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 193–196
196 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIMost pregnant women with B19V infection will have a
satisfactory outcome; however, the risk of hydrops fetalis has
been estimated to be around 3% and overall excess fetal loss
rate around 9% if infection is acquired before 20 weeks of
pregnancy [3]. In keeping with this, an overall fetal loss rate of
9% (3/33) was observed in this study in this group. However, a
much higher frequency of fetal loss was observed in those in
whom B19V infection was already demonstrated before or at
booking at 10 weeks (25%; 3/12). In comparison, no pregnan-
cies were lost where acute B19V infection occurred after a
gestational age of 12 weeks (0/21; p <0.05 by Fisher exact
probability test). Fetal losses are only investigated for B19V if
post-mortem ﬁndings are suggestive of it (i.e. hydrops or
anaemia); only 6 of 188 fetal losses occurring before or at the
time of delivery were investigated for B19V infection by PCR in
the Edinburgh area during 2013 (data not shown). From those,
one additional B19V infection leading to fetal loss at 22 weeks of
gestation was identiﬁed. Furthermore since pregnancies lost in
earlier stages are rarely investigated further (approximately
3000 per year in the Edinburgh area), the numbers of fetal
losses due to B19V infections are likely to be signiﬁcantly
underestimated. These results suggest that more efforts should
be targeted to investigate suspected B19V infections in early
pregnancy as well as the early gestation losses. Early screening
at 10 weeks of gestation would identify those with acute B19V
infection and so enable appropriate management to prevent
fetal loss.
In the light of improved diagnostic testing, the need for
possible inclusion of B19V testing in antenatal screening should
be re-evaluated. At the same time, more structured virological
and public health data collection on acute B19V infections and
fetal losses would be beneﬁcial for planning further
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